Company: BGLC
Filing Date: 2025-07-30
Form Type: 8-K
Source: 0001477932-25-005322
Chunk: 0

Company: BioNexus Gene Lab Corp
Filing Date: 2025-07-30
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure

On July 30, 2025, BioNexus Gene Lab Corp. (the “ Company” or “ BGLC”) issued a press release announcing that it has entered into a non-binding term sheet with Fidelion Diagnostics Pte Ltd regarding a contemplated cross-equity strategic alliance and exclusive commercialization rights for Fidelion’s VitaGuard™ minimal-residual-disease platform in Southeast Asia. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 and in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“ Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statement and Exhibits.